155 related articles for article (PubMed ID: 23252594)
1. Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study.
Argyriou AA; Briani C; Cavaletti G; Bruna J; Alberti P; Velasco R; Lonardi S; Cortinovis D; Cazzaniga M; Campagnolo M; Santos C; Kalofonos HP
Eur J Neurol; 2013 May; 20(5):788-94. PubMed ID: 23252594
[TBL] [Abstract][Full Text] [Related]
2. Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients.
Velasco R; Bruna J; Briani C; Argyriou AA; Cavaletti G; Alberti P; Frigeni B; Cacciavillani M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Kalofonos HP
J Neurol Neurosurg Psychiatry; 2014 Apr; 85(4):392-8. PubMed ID: 23813745
[TBL] [Abstract][Full Text] [Related]
3. Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study.
Briani C; Argyriou AA; Izquierdo C; Velasco R; Campagnolo M; Alberti P; Frigeni B; Cacciavillani M; Bergamo F; Cortinovis D; Cazzaniga M; Bruna J; Cavaletti G; Kalofonos HP
J Peripher Nerv Syst; 2014 Dec; 19(4):299-306. PubMed ID: 25582667
[TBL] [Abstract][Full Text] [Related]
4. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study.
Argyriou AA; Cavaletti G; Antonacopoulou A; Genazzani AA; Briani C; Bruna J; Terrazzino S; Velasco R; Alberti P; Campagnolo M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Psaromyalou A; Angelopoulou A; Kalofonos HP
Cancer; 2013 Oct; 119(19):3570-7. PubMed ID: 23821303
[TBL] [Abstract][Full Text] [Related]
5. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer.
Argyriou AA; Cavaletti G; Briani C; Velasco R; Bruna J; Campagnolo M; Alberti P; Bergamo F; Cortinovis D; Cazzaniga M; Santos C; Papadimitriou K; Kalofonos HP
Cancer; 2013 Jan; 119(2):438-44. PubMed ID: 22786764
[TBL] [Abstract][Full Text] [Related]
6. Rechallenge with oxaliplatin and peripheral neuropathy in colorectal cancer patients.
Besora S; Santos C; Izquierdo C; Martinez-Villacampa MM; Bruna J; Velasco R
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1793-1801. PubMed ID: 29955956
[TBL] [Abstract][Full Text] [Related]
7. Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis.
Terrazzino S; Argyriou AA; Cargnin S; Antonacopoulou AG; Briani C; Bruna J; Velasco R; Alberti P; Campagnolo M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Kalofonos HP; Canonico PL; Genazzani AA; Cavaletti G
J Peripher Nerv Syst; 2015 Mar; 20(1):15-23. PubMed ID: 25858589
[TBL] [Abstract][Full Text] [Related]
8. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
[TBL] [Abstract][Full Text] [Related]
9. Incidence, severity, longitudinal trends and predictors of acute and chronic oxaliplatin-induced peripheral neuropathy in Taiwanese patients with colorectal cancer.
Hsu SY; Huang WS; Lee SH; Chu TP; Lin YC; Lu CH; Beaton RD; Jane SW
Eur J Cancer Care (Engl); 2019 Mar; 28(2):e12976. PubMed ID: 30536809
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of Oxaliplatin-induced Chronic Neuropathy and Influencing Factors in Patients with Colorectal Cancer in Iran.
Shahriari-Ahmadi A; Fahimi A; Payandeh M; Sadeghi M
Asian Pac J Cancer Prev; 2015; 16(17):7603-6. PubMed ID: 26625769
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin rechallenge in metastatic colorectal cancer patients with clinically significant oxaliplatin-induced peripheral neurotoxicity.
Argyriou AA; Kalofonou F; Litsardopoulos P; Anastopoulou GG; Kalofonos HP
J Peripher Nerv Syst; 2021 Mar; 26(1):43-48. PubMed ID: 33345432
[TBL] [Abstract][Full Text] [Related]
12. Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer.
Lucchetta M; Lonardi S; Bergamo F; Alberti P; Velasco R; Argyriou AA; Briani C; Bruna J; Cazzaniga M; Cortinovis D; Cavaletti G; Kalofonos HP
Cancer Chemother Pharmacol; 2012 Dec; 70(6):899-902. PubMed ID: 23108696
[TBL] [Abstract][Full Text] [Related]
13. Pregabalin for the Prevention of Oxaliplatin-Induced Painful Neuropathy: A Randomized, Double-Blind Trial.
de Andrade DC; Jacobsen Teixeira M; Galhardoni R; Ferreira KSL; Braz Mileno P; Scisci N; Zandonai A; Teixeira WGJ; Saragiotto DF; Silva V; Raicher I; Cury RG; Macarenco R; Otto Heise C; Wilson Iervolino Brotto M; Andrade de Mello A; Zini Megale M; Henrique Curti Dourado L; Mendes Bahia L; Lilian Rodrigues A; Parravano D; Tizue Fukushima J; Lefaucheur JP; Bouhassira D; Sobroza E; Riechelmann RP; Hoff PM; ; Valério da Silva F; Chile T; Dale CS; Nebuloni D; Senna L; Brentani H; Pagano RL; de Souza ÂM
Oncologist; 2017 Oct; 22(10):1154-e105. PubMed ID: 28652279
[TBL] [Abstract][Full Text] [Related]
14. Electroclinical biomarkers of early peripheral neurotoxicity from oxaliplatin.
McHugh JC; Tryfonopoulos D; Fennelly D; Crown J; Connolly S
Eur J Cancer Care (Engl); 2012 Nov; 21(6):782-9. PubMed ID: 22594346
[TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer.
Griffith KA; Zhu S; Johantgen M; Kessler MD; Renn C; Beutler AS; Kanwar R; Ambulos N; Cavaletti G; Bruna J; Briani C; Argyriou AA; Kalofonos HP; Yerges-Armstrong LM; Dorsey SG
J Pain Symptom Manage; 2017 Nov; 54(5):701-706.e1. PubMed ID: 28743660
[TBL] [Abstract][Full Text] [Related]
16. Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin.
Tofthagen C; McAllister RD; McMillan SC
Clin J Oncol Nurs; 2011 Apr; 15(2):182-8. PubMed ID: 21444285
[TBL] [Abstract][Full Text] [Related]
17. Liability of the voltage-gated potassium channel KCNN3 repeat polymorphism to acute oxaliplatin-induced peripheral neurotoxicity.
Argyriou AA; Antonacopoulou AG; Alberti P; Briani C; Bruna J; Velasco R; Anastopoulou GG; Park SB; Cavaletti G; Kalofonos HP
J Peripher Nerv Syst; 2019 Dec; 24(4):298-303. PubMed ID: 31486252
[TBL] [Abstract][Full Text] [Related]
18. The effect of diabetes on oxaliplatin-induced peripheral neuropathy.
Uwah AN; Ackler J; Leighton JC; Pomerantz S; Tester W
Clin Colorectal Cancer; 2012 Dec; 11(4):275-9. PubMed ID: 22682776
[TBL] [Abstract][Full Text] [Related]
19. Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer.
Argyriou AA; Polychronopoulos P; Iconomou G; Koutras A; Makatsoris T; Gerolymos MK; Gourzis P; Assimakopoulos K; Kalofonos HP; Chroni E
Acta Oncol; 2007; 46(8):1131-7. PubMed ID: 17851880
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry.
Mols F; Beijers T; Lemmens V; van den Hurk CJ; Vreugdenhil G; van de Poll-Franse LV
J Clin Oncol; 2013 Jul; 31(21):2699-707. PubMed ID: 23775951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
